Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma
Esophageal Carcinoma, Neoadjuvant Immunotherapy
About this trial
This is an interventional treatment trial for Esophageal Carcinoma
Eligibility Criteria
Inclusion Criteria: age ≥ 18 years and ≤89 years; pathological histological examination confirmed the diagnosis of esophageal squamous cell carcinoma and esophageal adenocarcinoma; clinical stage II-IVA; adequate organ function; no previous chemotherapy or radiotherapy; voluntarily signed informed consent. Exclusion Criteria: the presence of concurrent malignancies that interfere with the prognosis of esophageal cancer; patients with immunodeficiency or autoimmune diseases that seriously affect the body's immune system, such as those who test positive for HIV; patients undergoing systemic corticosteroid or other immunosuppressive treatments; patients with a history of allergy to the components of this test drug.
Sites / Locations
- Qin liRecruiting
Arms of the Study
Arm 1
Experimental
Neoadjuvant PD-1 Blockade Plus Chemotherapy
PD-1 blockade, 200 mg, IV., every 3 weeks, 2-3 cycles; Albumin paclitaxel, 300 mg/m2, IV., every 3 weeks, 2-3 cycles; Carboplatin/Nedaplatin, area under the curve = 5, IV., every 3 weeks, 2-3 cycles.